Please assess the completion status of the following clinical trial:

Trial Title: Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of Smoldering or Indolent myeloma~* All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines.~Exclusion Criteria:~* Prior bisphosphonate therapy within 30 days prior to study entry.~* Serum creatinine \> 5 mg/dl, ascites, or serum direct bilirubin \> 2.5 mg/dl.~* Prior plicamycin or calcitonin within 2 weeks of study entry.~* Severe cardiac disease, unstable thyroid disease, or epilepsy.~* Prior radiation therapy to \> 20% of the skeleton.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thalidomide + Bisphosphonate (Type: EXPERIMENTAL): 200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).